title: Folate deprivation induces BCRP (ABCG2) expression and mitoxantrone resistance in Caco-2 cells.
abstract: Folates can induce the expression and activity of the breast-cancer-resistance-protein (BCRP) and the multidrug-resistance-protein-1 (MRP1). Our aim was to study the time-dependent effect of folate deprivation/supplementation on (i) BCRP and MRP expression and (ii) on drug resistance mediated by these transporters. Therefore Caco-2 colon cancer cells usually grown in standard RPMI-medium containing supraphysiological folic acid (FA) concentrations (2.3 muM; high-folate, HF) were gradually adapted to more physiological folate concentrations (1 nM leucovorin (LV) or 1 nM FA; low-folate, LF), resulting in the sublines Caco-2-LF/LV and Caco-2-LF/FA. Caco-2-LF/LV and LF/FA cells exhibited a maximal increase of 5.2- and 9.6-fold for BCRP-mRNA and 3.9- and 5.7-fold for BCRP protein expression, respectively, but no major changes on MRP expression. Overexpression of BCRP in the LF-cells resulted in 3.6- to 6.3-fold resistance to mitoxantrone (MR), which was completely reverted by the BCRP inhibitor Ko143. On the other hand, LF-adapted cells were markedly more sensitive to methotrexate than the HF-counterpart, both after 4-hr (9,870- and 23,923-fold for Caco-2-LF/LV and LF/FA, respectively) and 72-hr (11- and 22-fold for Caco-2-LF/LV and LF/FA, respectively) exposure. Immunofluorescent staining observed with a confocal-laser-scan-microscope revealed that in Caco-2 cells (both HF and LF), BCRP is mainly located in the cytoplasm. In conclusion, folate deprivation induces BCRP expression associated with MR resistance in Caco-2 cells. The intracellular localization of BCRP in these cells suggests that this transporter is not primarily extruding its substrates out of the cell, but rather to an intracellular compartment where folates can be kept as storage.
authors.affiliation: Department of Biochemistry (U38-FCT), Faculty of Medicine, University of Porto, Porto, Portugal. c.lemos@vumc.nl
authors.forename: Clara
authors.initials: C
authors.lastname: Lemos
authors.forename: Ietje
authors.initials: I
authors.lastname: Kathmann
authors.forename: Elisa
authors.initials: E
authors.lastname: Giovannetti
authors.forename: Henk
authors.initials: H
authors.lastname: Dekker
authors.forename: George L
authors.initials: GL
authors.lastname: Scheffer
authors.forename: Conceição
authors.initials: C
authors.lastname: Calhau
authors.forename: Gerrit
authors.initials: G
authors.lastname: Jansen
authors.forename: Godefridus J
authors.initials: GJ
authors.lastname: Peters
mesh_terms: D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters / Q000037:antagonists & inhibitors / Q000235:genetics*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D018938:Caco-2 Cells; D019008:Drug Resistance, Neoplasm; D005492:Folic Acid / Q000008:administration & dosage*; D006801:Humans; D008942:Mitoxantrone / Q000494:pharmacology*; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors / Q000235:genetics*; D012333:RNA, Messenger / Q000235:genetics
chemical_list: C116614:ABCG2 protein, human; D000070997:ATP Binding Cassette Transporter, Subfamily G, Member 2; D018528:ATP-Binding Cassette Transporters; D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D012333:RNA, Messenger; D005492:Folic Acid; D008942:Mitoxantrone